Journal
AUTOIMMUNITY REVIEWS
Volume 20, Issue 1, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.autrev.2020.102712
Keywords
Minimal manifestation status (MMS); Autoimmune; Anti-AChR antibody; Anti-MuSK antibody; Eculizumab; Efgartigimod
Categories
Ask authors/readers for more resources
Myasthenia gravis is an autoimmune disease of the neuromuscular junction, and treatment requires careful consideration to avoid the risks associated with long-term systemic steroid administration. Emerging therapies for MG focus on using biological drugs and targeting new pathways of the immune system to address disease heterogeneity.
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction. Immunosuppressive treatments are part of the therapeutic armamentarium in MG. Long-term systemic steroid administration carry considerable risks and adverse events. Consequently, steroid-free immunosuppressive therapy is necessary to reduce the dose or discontinue steroids. First immunosuppressive drug trials in MG were performed in the mid-60s using standard and nonspecific immunosuppression. Since then, only few randomized controlled clinical trials were conducted in MG and assesed drug efficacy in terms of its steroid-sparing capacity and the ability to reduce myasthenic signs and symptoms. Treatment strategy in MG is quite challenging, mainly due to the disease heterogeneity in terms of clinical presentation, immunopathogenesis and drug response. To solve this dilemma, emerging treatment are based on biological drugs and use new targets of the immune pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available